Crinetics Pharmaceuticals Q1 2024 GAAP EPS $(0.93) Misses $(0.81) Estimate, Sales $640.000K Beat $255.556K Estimate
Crinetics Pharmaceuticals Q1 2024 GAAP EPS $(0.93) Misses $(0.81) Estimate, Sales $640.000K Beat $255.556K Estimate
Crinetics Pharmicals 2024年第一季度GAAP每股收益美元（0.93美元）未達到預期（0.81美元），銷售額爲640.000萬美元，超過255.556萬美元的預期
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.81) by 14.81 percent. This is a 9.41 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $640.000 thousand which beat the analyst consensus estimate of $255.556 thousand by 150.43 percent. This is a 76.11 percent decrease over sales of $2.679 million the same period last year.
Crinetics Pharmicals（納斯達克股票代碼：CRNX）公佈的季度虧損爲每股0.93美元，比分析師普遍預期的0.81美元（0.81美元）低14.81％。與去年同期每股虧損0.85美元（0.85）相比，下降了9.41％。該公司公佈的季度銷售額爲64萬美元，比分析師普遍預期的255,556美元高出150.43％。這比去年同期的267.9萬美元的銷售額下降了76.11％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。